The UCL-led study, mostly on tirzepatide, reported 91.4% of women still on treatment at six months. SheMed, the company running the program, co-authored it.
Recap by typeshit. Full story at AOL.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
Koufakis and colleagues pooled trial data in Advances in Therapy. In the SEMALEAN study, handgrip strength rose 4.5 kg at 12 months on semaglutide.
BCG found GLP-1 users plan to spend 11% more on high-protein food, while Reuters found brands inflating protein claims with bigger serving sizes.
Loading…